HER2 remains a highly promising therapeutic target due to its efficient receptor-mediated endocytosis, high surface expression, and well-established role in breast cancer progression of its rapid receptor-mediated endocytosis after ADC binding [40]. This evidence concerns the gene ERBB2 and breast carcinoma.